DLRC Pharma Services has the experience of acting as the legal representative of the EU. We are able to advise you on EU clinical trial requirements and provide oversight to ensure your study is approved and conducted in accordance with EU legislation. For any country that is not part of the EU, there are no requirements for local legal representatives under the Clinical Trials Directive. However, there may be local laws or regulations that apply. Sponsors who are not located in the EU/EEA must appoint a legal representative based in the EU/EEA. If the promoter has an office/address registered in the EU, it does not need a legal representative. In addition, ARG strives to build a structure that can be maintained throughout the partnership cycle, with a focus on higher-level considerations, such as: the legal implications of managing a single project versus a multi-stage program, and then planning and executing how best to move forward. (*) Critical processes: data on health care, ethnicity, race, politics, trade unions, religious beliefs, children, the elderly or harmful persons and any massive processing of personal data enabling the profiling of individuals. An epidemiological or clinical trial is a critical process. Depending on the internal organisational structure, this option only applies to organisations that conduct their clinical trial activities in-house or whose sponsor and legal representative are permanently based in the European Union. Any sponsor conducting a study in the European Union (EU) and not having a registered office in the territory of the European Economic Area (e.g. the United States or Japan or any other territory outside the EU), is required by the Commission of the European Union by its Directive 2001/20/EC to cooperate with a legal representative in one of these countries. Legal representation represents a potential conflict of interest for CROs, which is why it is so important to understand what this role entails.

The question that CROs need to ask themselves is whether they feel comfortable taking on this responsibility for a sponsor? We act as your legal representative for official recognition as a small and medium-sized enterprise (SME) with the European Medicines Agency (EMA). Lumis has been granted SME status by the EMA. Not necessarily. If the EU branch does not feel comfortable doing so, is not sufficiently equipped (i.e. only has production facilities without regulatory or clinical staff) or if this could potentially lead to a conflict of interest or intellectual property risk (due to country-specific partnership agreements, etc.), the role of legal representative may be outsourced to an external party. like IDEA Regulatory. The establishment of legal representation for a proponent (e.g., the time elapsed between the approval of the cost proposal and the receipt of the fully executed DSO or work order) varies considerably depending on the proponent`s bureaucratic systems, but could be cancelled by IDEA Regulatory (MSA generated, approved, signed and sent to the proponent) in less than a week, unless significant changes to the contract are requested. No. A legal representative is not required in all Member States. If a multicentre study is carried out, a European office is sufficient. No, because an offer of legal representation is all that IDEA Regulatory requires: If QbD Clinical acts as the sponsor`s legal representative, the sponsor is not required to establish an office in the EEA during the clinical phase.

The following information is required to create a tailored cost proposal for legal representation: Since regulations inevitably change, there are always a few legal aspects in studies where a proponent asks questions such as „Did the governing body really mean that?“ or „What should we do to stay compliant?“ The underlying challenge in this dynamic landscape, beyond answering a specific question, is working with constantly informed legal representation. For studies taking place within the EU, the UK accepts a legal representative based in the EEA and meeting the requirements of the EU Clinical Trials Directive. In addition, the EU legal representative must monitor quality assurance throughout the scope of the procedure. Since this often includes aspects that are not only carried out in the EU, but also those that can be carried out outside the EU but are related to the study, it is imperative to find the right partner to comply with the study. The role of the CRO differs significantly from that of the legal representative, as does their experience and ability to advise the sponsor or to be the quality assurance for the sponsor`s quality assurance. In order for us to perform our duties as legal guardians and supervise your study, IDEA Regulatory requires the sponsor to keep us informed of all its regulatory, ethical, safety and quality assurance activities related to the study and to provide appropriate updates and modifications throughout the duration of the study. These documents include: According to the regulations, clinical trial sponsors will be able to use the Clinical Trials Information System (SITC) from January 31, 2022, but will not be required to use it immediately in accordance with a three-year transition period. National regulatory authorities in EU Member States and EEA countries will use SITC from 31 January 2022. According to the Clinical Trials Regulation, national regulatory authorities in EU Member States and EEA countries will be required to do so from the age of 31. January 2022 CTIS to fulfill its legal obligations regarding the evaluation and monitoring of clinical trials. However, another possibility is for organisations to set up a single, resourced central organisation under which all clinical trials in the EU are managed and conducted. The only resourced central organization would include both the role of sponsor and legal representative.

This would be advantageous as no legal representative would be required since the promoter is based in the EU. In future, according to the new EU Clinical Trials Regulation (CTR) and the MDR, the legal representative will be responsible for „guaranteeing“ the compliance of a non-EU sponsor. All competent authorities and ethics committees are informed via the contact details of the legal representatives and can contact them at any time if they need information about the study. However, this would normally only happen if the sponsor did not respond to a request within the set deadline.